SPONSORED SESSIONS
### Saturday 23 May 2015

<table>
<thead>
<tr>
<th>Topic</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>The failing heart: a team approach to address unmet needs for better patient care</td>
<td>Seville</td>
<td>12:15-13:45</td>
</tr>
<tr>
<td>Treating mitral regurgitation in heart failure patients: why Transcatheter Mitral Valve Repair (TMVR) and multidisciplinary care are key</td>
<td>Florence</td>
<td>12:15-13:15</td>
</tr>
<tr>
<td>Use of angiotensin II receptor blockers and heart failure</td>
<td>Athens</td>
<td>12:15-13:15</td>
</tr>
</tbody>
</table>

**Sponsored by**

- Novartis Pharma
- Abbott Vascular
- Takeda Pharmaceuticals

### Sunday 24 May 2015

<table>
<thead>
<tr>
<th>Topic</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Taking strides to improve outcomes in heart failure: today’s and tomorrow’s approaches</td>
<td>Seville</td>
<td>12:45-14:00</td>
</tr>
<tr>
<td>What’s hot in heart failure: defining unmet medical needs and innovative targets for therapy</td>
<td>Florence</td>
<td>12:45-14:00</td>
</tr>
<tr>
<td>Improving response of cardiac resynchronization therapy: patient selection, device therapy and patient care</td>
<td>Athens</td>
<td>12:45-14:00</td>
</tr>
<tr>
<td>Practical guidance on the use of oral factor Xa inhibitors in non-valvular atrial fibrillation: multidisciplinary perspectives</td>
<td>Paris</td>
<td>12:45-14:00</td>
</tr>
<tr>
<td>Changing conventions – Intravenous iron in heart failure</td>
<td>Madrid</td>
<td>12:45-14:00</td>
</tr>
<tr>
<td>SDB in Heart Failure, time to be serious about it!</td>
<td>Rome</td>
<td>12:45-13:45</td>
</tr>
</tbody>
</table>

**Sponsored by**

- Novartis Pharma
- Bayer HealthCare
- Medtronic
- Bristol-Myers Squibb and Pfizer
- Vifor Pharma
- ResMed
<table>
<thead>
<tr>
<th>Title</th>
<th>Room</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Preventing heart failure rehospitalization: a collaborative effort</td>
<td>Room Seville</td>
<td>18:15-19:45</td>
</tr>
<tr>
<td><strong>Sponsored by SERVIER</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Supported by Bayer Pharmaceuticals</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday 25 May 2015</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ask the experts: your questions answered on HF management and multidisciplinary approaches</td>
<td>Room Seville</td>
<td>12:45-14:00</td>
</tr>
<tr>
<td><strong>Supported by Novartis Pharma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Management of hypertension and diabetes in patients with heart failure</td>
<td>Room Florence</td>
<td>12:45-13:45</td>
</tr>
<tr>
<td><strong>Sponsored by Takeda Pharmaceuticals</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The RAASi Debate: Should RAAS Blockade Continue With a Declining eGFR?</td>
<td>Room Athens</td>
<td>12:45-14:00</td>
</tr>
<tr>
<td><strong>Sponsored by ZS Pharma, Inc.</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treating cardiac health one breath at a time:</td>
<td>Room Madrid</td>
<td>12:45-13:45</td>
</tr>
<tr>
<td>A new approach for treating central sleep apnea in HF patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sponsored by Charité University Berlin and Respocardia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Preventing Sudden Cardiac Death in the Newly Diagnosed Heart Failure Patient</td>
<td>Room Rome</td>
<td>12:45-13:45</td>
</tr>
<tr>
<td><strong>Sponsored by Zoll CMS GmbH</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitochondria in heart failure: a new target for therapy and recent first results</td>
<td>Room Florence</td>
<td>18:15-19:15</td>
</tr>
<tr>
<td><strong>Sponsored by Charité University Berlin and Stealth Peptides</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The patient perspective - Effects of levosimendan</td>
<td>Room Athens</td>
<td>18:15-19:15</td>
</tr>
<tr>
<td><strong>Supported by Orion Pharma</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SATELLITE SYMPOSIA - EXPERTS ON THE SPOT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monday 25 May 2015</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intravenous iron in heart Failure - Improving patient’s outcomes</td>
<td>AGORA</td>
<td>15:50-16:20</td>
</tr>
<tr>
<td><strong>Sponsored by Vifor Pharma</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Hands-On Room 1**
Hands-On Tutorials organised & sponsored by **ResMed**

"Practical aspects of Sleep Disordered Breathing Management in Heart Failure
The tools in cardiologists hands from screening to treatment”
Sunday 24 May, 10:00 -11:00
Monday 25 May, 10:00 -11:00
Preregistration to the session on ResMed booth #B70

**Hands-On Room 2**
Hands-On Tutorials organised & sponsored by **Abbott Vascular**

"Treating Mitral Regurgitation in Heart Failure Patient: From Diagnosis to Follow-up”
Sunday 24 May, 08:30 - 09:15 / 11:00 -11:45 / 14:00 -14:45
Monday 25 May, 08:30 - 09:15 / 11:00 -11:45 / 14:00 -14:45

"Hands-on Percutaneous Mitral Valve Repair: Device & Screening”
Sunday 24 May, 09:30 -10:30 / 12:00 -13:00 / 15:00 -16:00
Monday 25 May, 09:30 -10:30 / 12:00 -13:00 / 15:00 -16:00
Preregistration to the session on Abbott Vascular booth #B65

**Hands-On Room 3**
Hands-On Tutorials organised & sponsored by **HeartWare**

“Benefits of Ventricular Assist Device therapy for end-stage heart failure patients”
Sunday 24 May, 10:30 -11:30 / 12:30 -13:30 / 14:30 -15:30
Preregistration to the session on HeartWare booth #B40
Join an internationally renowned faculty, chaired by Professors John McMurray (UK) and Adriaan Voors (The Netherlands), for three educational lectures focusing on improving outcomes in heart failure.

**LECTURE I**
The failing heart: a team approach to address unmet needs for better patient care

Saturday, 23 May 2015  
12:15–13:45  
Seville room

This is an innovative programme of expert presentations and 3D animations

**LECTURE II**
Taking strides to improve outcomes in heart failure: today’s and tomorrow’s approaches

Sunday, 24 May 2015  
12:45–14:00  
Seville room

**LECTURE III – QUESTION TIME**
Ask the experts: your questions answered on HF management and multidisciplinary approaches

Monday, 25 May 2015  
12:45–14:00  
Seville room

These Satellite Symposia are organised and funded by Novartis Pharma AG
### LECTURE I – The failing heart: a team approach to address unmet needs for better patient care

Saturday 23 May 2015, 12:15–13:45  
Heart Failure 2015 / 2nd World Congress on Acute Heart Failure, Seville room, Sevilla Palacio de Congresos (FIBES II)

<table>
<thead>
<tr>
<th>Timing</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:15</td>
<td>Welcome and Introduction</td>
<td>Chairs</td>
</tr>
<tr>
<td>12:20</td>
<td>Journey through the failing heart</td>
<td>Video presentation</td>
</tr>
<tr>
<td>12:23</td>
<td>Acute heart failure: addressing the unmet treatment needs</td>
<td>Alexandre Mebazaa – France</td>
</tr>
<tr>
<td>12:38</td>
<td>A peek at the neurohormonal mechanisms of heart failure</td>
<td>Video presentation</td>
</tr>
<tr>
<td>12:41</td>
<td>Managing chronic heart failure: a review of current best practices and needs</td>
<td>Theresa McDonagh – UK</td>
</tr>
<tr>
<td>12:56</td>
<td>Heart failure impacts patients’ lives</td>
<td>Video presentation</td>
</tr>
<tr>
<td>12:59</td>
<td>A multidisciplinary team approach to managing HF: concerted team effort and benefits for patients</td>
<td>Anna Strömberg – Sweden</td>
</tr>
<tr>
<td>13:14</td>
<td>Patient perspectives</td>
<td>Patient – UK</td>
</tr>
<tr>
<td>13:29</td>
<td>Discussion and conclusion</td>
<td></td>
</tr>
</tbody>
</table>

Register now at [www.heartfailurelectureseries.com](http://www.heartfailurelectureseries.com) to access exclusive content.
Treating Mitral Regurgitation in Heart Failure patients: Why Transcatheter Mitral Valve Repair and Multidisciplinary care are key.
Chairman: Frank RUSCHITZKA (Zurich, Switzerland)

- **Introduction.**
  Frank RUSCHITZKA (Zurich, Switzerland)

- **Mitral regurgitation in heart failure patients: the importance to diagnose and treat.**
  Nina WUNDERLICH (Darmstadt, Germany)

- **WHEN should you refer your patient for intervention?**
  Francesco MAISANO (Zurich, Switzerland)

- **WHO can benefit from TMVR?**
  Ralph Stephan VON BARDELEBEN (Mainz, Germany)

- **WHY should you refer your patient to TMVR?**
  Piotr PONIKOWSKI (Wroclaw, Poland)

- **Take home messages.**
  Frank RUSCHITZKA (Zurich, Switzerland)

**Valves repaired. Lives improved.**
Transcatheter Mitral Valve Repair

Patient groups in which significant clinical benefits have been reported:

- Degenerative MR, declined for surgery
- Severe LV dysfunction refractory to medical therapy
- Severe Heart Failure, despite optimal medical therapy
- CRT non-responders
- Bivalvular Disease: Severe Aortic Stenosis and Mitral Regurgitation

The following parameters should be taken into consideration by the Heart Team:
Moderate to severe or severe MR (Functional or Degenerative)
Echocardiographic criteria for eligibility
Level of surgical risk
Greater than one year life expectancy


© 2014 Abbott. All rights reserved. 9-EH-1-4262-01 03-2014

Information contained herein is for international delegates from Europe, Middle East and Africa only. Product is subject to prior training requirement as per the instructions for use. This product is intended for use by or under the direction of a physician. Prior to use, it is important to read the package insert thoroughly for instructions for use, warnings and potential complications associated with the use of this device. Please check with the regulatory status of the device before distribution in areas where CE marking is not the regulation in force. All drawings are artist’s representations only and should not be considered as an engineering drawing or photograph. Photos on file at Abbott Vascular. All products herein are trademarks of the Abbott Group of Companies. The following should be considered by French health-care professionals only: Clip de réparation mitrale MitraClip et accessoires. Dispositifs médicaux de classe III et I, organismes notifiés BSI. Fabricué par Evalve Inc, mandataire européen Abbott Vascular BVBA. Se référer aux informations de la notice d’instructions qui décrivent les informations de bon usage du dispositif. Veuillez lire attentivement les instructions figurant dans la notice. Non pris en charge par les organismes d’assurance maladie. For more information, visit our website at abbottvascular.com © 2015 Abbott. All rights reserved. 9-EH-1-0947-01 03-2015
# Programme

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:15 - 12:20 | Welcome and Introduction  
Chair: Prof. Luis Ruilope (Spain) |
| 12:20 - 12:40 | Heart Failure in the Renin-Angiotensin System  
Prof. Robert Chilton (U.S.A.) |
| 12:40 - 13:00 | Importance of Blood Pressure Control in  
Heart Failure Management  
Prof. Luis Ruilope (Spain) |
| 13:00 - 13:15 | Discussion/Q&A |

Use of Angiotensin II Receptor Blockers and Heart Failure  
Takeda Satellite Symposium  
Athens Room I Sevilla Palacio de Congresos  
Saturday, 23 May 2015
Programme

12:15 - 12:20  Welcome and Introduction
   Chair: Prof. Luis Ruilope (Spain)

12:20 - 12:40  Heart Failure in the Renin-Angiotensin System
   Prof. Robert Chilton (U.S.A.)

12:40 - 13:00  Importance of Blood Pressure Control in Heart Failure Management
   Prof. Luis Ruilope (Spain)

13:00 - 13:15  Discussion/Q&A
Join an internationally renowned faculty, chaired by Professors John McMurray (UK) and Adriaan Voors (The Netherlands), for three educational lectures focusing on improving outcomes in heart failure.

LECTURE I
The failing heart: a team approach to address unmet needs for better patient care
Saturday, 23 May 2015
12:15–13:45
Seville room

LECTURE II
Taking strides to improve outcomes in heart failure: today’s and tomorrow’s approaches
Sunday, 24 May 2015
12:45–14:00
Seville room
Here we will take a look at current and future management approaches

LECTURE III – QUESTION TIME
Ask the experts: your questions answered on HF management and multidisciplinary approaches
Monday, 25 May 2015
12:45–14:00
Seville room

If you have missed lecture I, resources will be available post-congress at www.heartfailurelectureseries.com

Turn over the page to view the full agenda

These Satellite Symposia are organised and funded by Novartis Pharma AG

NOVARTIS PHARMACEUTICALS
### LECTURE II – Taking strides to improve outcomes in heart failure: today’s and tomorrow’s approaches

Sunday 24 May 2015, 12:45–14:00  
Heart Failure 2015 / 2nd World Congress on Acute Heart Failure, Seville room, Sevilla Palacio de Congresos (FIBES II)

<table>
<thead>
<tr>
<th>Timing</th>
<th>Title</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45</td>
<td>Welcome/introduction and the journey through HF</td>
<td>Chairs</td>
</tr>
<tr>
<td>12:50</td>
<td>Current practices in heart failure management: an interactive case study</td>
<td>Héctor Bueno – Spain</td>
</tr>
<tr>
<td>13:10</td>
<td>New therapies for acute heart failure</td>
<td>Javier Díez – Spain</td>
</tr>
<tr>
<td>13:30</td>
<td>New therapies for chronic heart failure</td>
<td>John McMurray – UK</td>
</tr>
<tr>
<td>13:50</td>
<td>Discussion and conclusion</td>
<td></td>
</tr>
</tbody>
</table>

Register now at [www.heartfailurelectureseries.com](http://www.heartfailurelectureseries.com). Registration includes exclusive access to webinars and resources relating to the lecture series and you can also submit your questions.
You need commitment, focus and passion to find new ways to fight the diseases of this world: Innovation is at the heart of it.

**Innovation for better health.** Our commitment is to bring to patients around the world quality medicines for use in diagnosing, combating and preventing disease. Every day we work against time, researching new pathways, new molecules, new technologies – complementing our own capabilities with expertise of innovative partners from science and industry.

The success of this work is evidenced in new medicines for areas with significant unmet medical need such as cardiovascular and blood diseases. Our aim is a better quality of life for all.

www.bayerhealthcare.com
www.bayerpharma.com
What’s hot in heart failure: Defining unmet medical needs and innovative targets for therapy.

Moderated by the chairmen Burkert Pieske & Marco Metra

**Sunday 24 May 2015, 12:45–14:00**

Sevilla Congress and Exhibition Centre, Spain
Level 1, Room Florence

12:45  Introduction and opening remarks  
Burkert Pieske, Germany

12:50  Comorbidities, differential diagnosis and phenotypic spectrum of HFpEF  
Burkert Pieske, Germany

13:05  Unmet medical needs in HFrEF and possible ways to address them  
Javed Butler, USA

13:20  The unique risk intersection of heart failure and diabetes: Lessons learned from real world evidence  
Carolyn Lam Su Ping, Singapore

13:35  Innovative promising targets in heart failure  
Mihai Gheorghiade, USA

13:55  Closing remarks  
Marco Metra, Italy

A Bayer HealthCare Satellite Symposium at Heart Failure 2015 / 2nd World Congress on Acute Heart Failure

© Bayer HealthCare  March 2015
Bayer Pharma AG, Müllerstr. 178, 13353 Berlin, Germany
Satellite Symposium

Sunday, 24 May 2015
12:45 - 14:00
Athens room

CHAIRMEN
G. Filippatos (Athens, GR)
K. Dickstein (Stavanger, NO)

The Satellite Symposium video will be available from 1 July 2015 on: www.medtronic.eu/heartfailure2015

12:45 INTRODUCTION
K. Dickstein (Stavanger, NO)

12:50 PATIENT SELECTION: HOW TO ENSURE REFERRAL OF THE RIGHT CANDIDATES FOR CRT?
S. Williams (Wythenshawe, GB)

13:10 AdaptivCRT: DYNAMIC LEFT VENTRICULAR PACING TO IMPROVE RESPONSE
A. Patwala (Stoke, GB)

13:30 CRT FOLLOW-UP: FROM DEVICE DIAGNOSTICS TO REMOTE MONITORING
R. Cozar-Leon (Seville, ES)

13:50 CONCLUSIONS
G. Filippatos (Athens, GR)

Improving response of Cardiac Resynchronization Therapy: Patient selection, device therapy and patient care

Innovating for life.
Visit the Medtronic Booth B90
Discover solutions to manage your Heart Failure patients across the continuum of care

ScreenLink Calculator
Download the cardiology referral tool from the App store and Google Play or visit www.screenlinkcalculator.com
Practical guidance on the use of oral factor Xa inhibitors in non-valvular atrial fibrillation: multidisciplinary perspectives

Satellite Symposium, Sunday 24th May 2015, 12:45 – 14:00
Paris Room, Congress Centre (Palacio de Congresos), Seville, Spain

This Satellite Symposium is fully organised and funded by:

Bristol-Myers Squibb  Pfizer

Date of preparation: March 2015  EUAPI830
Please join our internationally-renowned faculty, chaired by Professors José López-Sendón (Spain) and Michael Böhm (Germany), who will present real-world evidence and clinical trial data, and discuss optimization of care in patients with NVAF receiving anticoagulation with oral factor Xa inhibitors from the multidisciplinary perspectives of the nephrologist, cardiologist, and haematologist.

We look forward to welcoming you to what promises to be an interesting and informative session.

**Agenda**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 – 12:50</td>
<td>Welcome and introduction</td>
<td>José López-Sendón – Spain</td>
</tr>
<tr>
<td>12:50 – 13:00</td>
<td>How big is the problem? Unmet medical needs in patients with NVAF: focus on renal impairment and elderly – insights from the nephrologist</td>
<td>Luis Ruilope – Spain</td>
</tr>
<tr>
<td>13:00 – 13:15</td>
<td>How to manage stroke prevention in patients with NVAF and renal impairment – insights from the cardiologist</td>
<td>José López-Sendón – Spain</td>
</tr>
<tr>
<td>13:15 – 13:30</td>
<td>Management of patients with NVAF – evidence from the ARISTOTLE study with apixaban</td>
<td>Michael Böhm – Germany</td>
</tr>
<tr>
<td>13:45 – 13:55</td>
<td>Q&amp;A and panel discussion</td>
<td>All</td>
</tr>
<tr>
<td>13:55 – 14:00</td>
<td>Concluding comments</td>
<td>Michael Böhm – Germany</td>
</tr>
</tbody>
</table>
Satellite Symposium

*Changing Conventions - Intravenous Iron in Heart Failure*

Sunday, 24\textsuperscript{th} May 2015
12:45 – 14:00 Room Madrid

Please visit us at our booth A50 next to Agora.

Heart Failure 2015
2nd World Congress on Acute Heart Failure
Satellite Symposium

**Changing Conventions – Intravenous Iron in Heart Failure**
Sunday, 24th May 2015, 12:45 – 14:00 Room Madrid

**Programme**

**Chair:**  Karl Swedberg, Sweden  
José Ramón González Juanatey, Spain

12:45 – 12:50  **Introduction**  
José Ramón González Juanatey, Spain

12:50 – 13:05  **Iron deficiency - a common neglected burden in heart failure clinical management and its diagnosis**  
John Cleland, United Kingdom

13:05 – 13:30  **Improving outcome with intravenous iron in iron deficient heart failure patients**  
Stefan Anker, Germany

13:30 – 13:45  **Why does intravenous iron work?**  
Ewa Jankowska, Poland

13:45 – 14:00  **Panel discussion**  
Karl Swedberg, Sweden

Lunch will be provided
ResMed Satellite Symposium programme

- Interested in sleep disordered breathing and heart failure?
  Come and attend our Satellite Symposium
  **Sleep disordered breathing in heart failure, time to be serious about it!**
  **Sunday 24/05, 12:45 - 13:45, Rome Room**
  Chairs: Pr Andrew Coats, London, UK
  Pr Frank Ruschitzka, Zürich, CH
  1. Is it all about central apnoea?
     Dr Peter Van Der Meer, Groningen, NL
  2. What should be the therapeutic goals?
     Pr Martin Cowie, London, UK
  3. Non compliance to PAP therapy - Myth or reality?
     Pr Olaf Oldenburg, Bad Oeynhausen, DE

- Want to know more?
  Come and attend our Hands-On Tutorials
  **Practical aspects of sleep disordered breathing management in heart failure - The tools in cardiologists hands from screening to treatment**
  **Sunday 24/05, 10:00 - 11:00, Hands-On Room 1**
  **Monday 25/05, 10:00 - 11:00, Hands-On Room 1**
  Chair: Dr Christoph Schöbel, Charité Hospital, Berlin, DE

And discover our new range of solutions **on booth B70**
Treatment of sleep-disordered breathing by MV-ASV adaptive servo-ventilation in HF patients

**SERVE-HF** is a landmark study evaluating the use of minute ventilation targeted adaptive servo-ventilation (MV-ASV) for the treatment of sleep-disordered breathing (SDB) in patients with heart failure (HF), throughout Europe and Australia.

SERVE–HF is the first long-term randomised, controlled, international, multicentre study designed to assess the effects of MV-adaptive servo-ventilation on morbidity and mortality in patients with symptomatic chronic heart failure with reduced left ventricular ejection fraction (LVEF) and predominant central sleep apnoea–Cheyne-Stokes respiration (CSA–CSR).

To know more, visit ServeHF.com or visit us on booth B70
Satellite Symposium organized by Servier

Scientific programme

Preventing heart failure rehospitalization: a collaborative effort

Chairpersons:
**G.S. Filippatos** (Greece)
**M. Komajda** (France)

Introduction
**G.S. Filippatos** (Greece)

Defining the vulnerable heart failure patient
**P. Ponikowski** (Poland)

Ivabradine to improve cardiac function
**C. Maack** (Germany)

Let’s decide together how to prevent rehospitalization
Moderator: **M.R. Cowie** (UK)
Panelists: **M. Böhm** (Germany), **J.S. Borer** (US), **M. Komajda** (France), **A.A. Voors** (The Netherlands)

Conclusion
**M. Komajda** (France)

Interactive question and answer session via a voting system
Leading independent French pharmaceutical group

Over 21,400 employees. Over 3,000 researchers preparing tomorrow’s medicines. 25% of turnover invested in Research and Development in 2014. 29 drug candidates currently under development in the following therapeutic fields: cardiovascular diseases, central nervous system and psychiatry, cancer, diabetes and metabolism, and rheumatology. Present in 146 countries over 5 continents. 92% of SERVIER’s medicines are prescribed internationally. A turnover of 4 billion euros for 2014. SERVIER is the 8th European R&D investor in the pharmaceutical sector.
Reduce clot risk
Protect your patients

Driving innovation in the venous arterial thromboembolic area

To learn more about thrombosis, please visit www.thrombosisadviser.com

Visit the Bayer booth #C70
Novel oral anticoagulant use in patients with heart failure: Present and future perspectives

Moderated by the chairmen Faiez Zannad & José López-Sendón

Sunday 24 May 2015, 18:15–19:45

Sevilla Congress and Exhibition Centre, Spain
Level 1, Room Florence

18:15 Welcome and introduction
Faiez Zannad, France

18:20 The clinical burden of heart failure: A 'real-world' picture
Marco Metra, Italy

18:35 Worsening heart failure in patients with coronary artery disease: Pathophysiology revisited
Stefan Anker, Germany

18:55 Oral anticoagulation in patients with heart failure: Today and tomorrow
John Cleland, UK

19:15 Broadening clinical experience of novel oral anticoagulation in the cardiology setting
Faiez Zannad, France

19:30 Questions and answers
All

19:40 Summary and close
José López-Sendón, Spain

A Bayer HealthCare Satellite Symposium at Heart Failure 2015 / 2nd World Congress on Acute Heart Failure
Lecture III is your opportunity to engage with the entire faculty from lectures I and II, as you will be able to ask your own questions to stimulate the discussion.

**LECTURE I**  
The failing heart: a team approach to address unmet needs for better patient care  
Saturday, 23 May 2015  
12:15–13:45  
Seville room

**LECTURE II**  
Taking strides to improve outcomes in heart failure: today’s and tomorrow’s approaches  
Sunday, 24 May 2015  
12:45–14:00  
Seville room

**LECTURE III – QUESTION TIME**  
Ask the experts: your questions answered on HF management and multidisciplinary approaches  
Monday, 25 May 2015  
12:45–14:00  
Seville room

This will be your opportunity to put the faculty on the spot with your own questions and discussion points.

If you have missed lectures I & II, resources will be available post-congress at www.heartfailurelectureseries.com

Turn over the page to view further details on lecture III

These Satellite Symposia are organised and funded by Novartis Pharma AG
### LECTURE III – Ask the experts: your questions answered on HF management and multidisciplinary approaches

**Monday 25 May 2015, 12:45-14:00**
Heart Failure 2015 / 2nd World Congress on Acute Heart Failure, Seville room, Sevilla Palacio de Congresos (FIBES II)

<table>
<thead>
<tr>
<th>Timing</th>
<th>Title</th>
<th>Expert panel</th>
</tr>
</thead>
</table>
| 12:45  | Question time – a leading science moderator will chair this fully interactive discussion on heart failure | Héctor Bueno – Spain  
Javier Díez – Spain  
Alexandre Mebazaa – France  
John McMurray – UK  
Theresa McDonagh – UK  
Anna Strömberg – Sweden  
Adriaan Voors – The Netherlands |

During this 75 minute session, delegates will have the opportunity to ask their questions to the expert faculty

Register now at [www.heartfailurelectureseries.com](http://www.heartfailurelectureseries.com). Once registered, you can submit your questions for discussion among the expert panel during lecture III. Registration includes exclusive access to webinars and resources relating to the lecture series.

These Satellite Symposia are organised and funded by Novartis Pharma AG
Management of Hypertension and Diabetes in Patients With Heart Failure

Sevilla Palacio de Congresos
Florence Room
Monday, 25 May 2015

Programme Agenda

12:45 - 12:50  Welcome and Overview
Chair: Prof. Sanjay Rajagopalan (U.S.A.)

12:50 - 13:10  What Do and Don’t the Guidelines Tell Us About Treating the Diabetic Hypertensive Patient With Comorbid Heart Failure
Prof. Sanjay Rajagopalan (U.S.A.)

13:10 - 13:30  Treatment of Patients With Hypertension and Heart Failure and Patients With Diabetes and Heart Failure
Prof. Robert Chilton (U.S.A.)

13:30 - 13:45  Discussion/Q&A
Management of Hypertension and Diabetes in Patients With Heart Failure

Sevilla Palacio de Congresos
Florence Room
Monday, 25 May 2015

Programme Agenda

12:45 - 12:50 Welcome and Overview
Chair: Prof. Sanjay Rajagopalan (U.S.A.)

12:50 - 13:10 What Do and Don’t the Guidelines Tell Us About Treating the Diabetic Hypertensive Patient With Comorbid Heart Failure
Prof. Sanjay Rajagopalan (U.S.A.)

13:10 - 13:30 Treatment of Patients With Hypertension and Heart Failure and Patients With Diabetes and Heart Failure
Prof. Robert Chilton (U.S.A.)

13:30 - 13:45 Discussion/Q&A
A live interactive debate with leading experts in **Cardiology** and **Nephrology**.

**Monday, May 25, 2015** | 12.45 to 14.00
Athens Room | Lunch will be provided.

Wishing you would visit!
Should RAAS Blockade Continue with a Declining eGFR?

EXPERT DEBATE TEAM #1

Stefan D. Anker, MD, PhD
Göttingen, Germany

Adrian Covic, MD, PhD, FRCP (London), FERA
Iasi, Romania

EXPERT DEBATE TEAM #2

Dirk Jan van Veldhuisen, MD, PhD, FESC, FACC
Groningen, The Netherlands

Johannes F. Mann, MD
Munchen, Germany

THE ESTEEMED MODERATOR

Marisa Crespo-Leiro, MD, PhD
La Coruña, Spain
Treating cardiac health one breath at a time: A new approach for treating central sleep apnea in HF patients

MONDAY, MAY 25, 2015
12:45 - 13:45
MADRID ROOM

CHAIRS
Gerasimos Filippatos
Athens, Greece
Andrew J. S. Coats
Melbourne, Australia

SPEAKERS
William T. Abraham
Columbus, OH, USA
Maria Rosa Costanzo
Naperville, IL, USA
Piotr Ponikowski
Wrocław, Poland
Stephan von Haehling
Göttingen, Germany

Organised by CHARITÉ
Support by an unrestricted grant provided by Respocardia®
Treating cardiac health one breath at a time: A new approach for treating central sleep apnea in HF patients

MONDAY, MAY 25, 2015 ● 12:45 - 13:45
MADRID ROOM

- What a Busy Cardiologist Needs to Know about Sleep
  Stephan von Haehling, Göttingen, Germany

- Mechanisms and Clinical Consequences of CSA in HF patients
  Piotr Ponikowski, Wroclaw, Poland

- Treating CSA with Phrenic Nerve Stimulation
  William T. Abraham, Columbus, OH, USA

- Pivotal Trial of Phrenic Nerve Stimulation System
  Maria Rosa Costanzo, Naperville, IL, USA

- Panel Discussion
Mitochondria in heart failure: a new target for therapy and recent first results

MONDAY, MAY 25, 2015
18:15 - 19:15
ROOM: FLORENCE

CHAIRS
Gerasimos Filippatos, Athens, Greece
Piotr Ponikowski, Wroclaw, Poland

SPEAKERS
William T. Abraham, Columbus, OH, United States
Stefan D. Anker, Göttingen, Germany
John G. Cleland, London, United Kingdom
Hani Sabbah, Detroit, MI, United States
Mitochondria in heart failure: a new target for therapy and recent first results

Systolic heart failure and mitochondria: rationale of a novel treatment target and mechanism of action of Bendavia
Hani Sabbah, Detroit, MI, United States

Initial clinical trial results with Bendavia in CKD and ACS
William T. Abraham, Columbus, OH, United States

Initial clinical trial results with Bendavia in heart failure
Stefan D. Anker, Göttingen, Germany

Clinical development concepts moving forward
John G. Cleland, London, UK

Panel discussion

Organised by CHARITÉ

Supported by an unrestricted grant provided by Stealth Biotherapeutics
Please join us at the Satellite Symposium on

The patient perspective: effects of levosimendan on hemodynamics and quality of life

on Monday, May 25, at 18:15-19:15 in room Athens
FACULTY AND PROGRAM:

**Chairs:**
- Markku S. Nieminen
  Helsinki, Finland
- Ferenc Follath
  Zürich, Switzerland
- Frank Ruschitzka
  Zürich, Switzerland

**Ferenc Follath**
Zürich, Switzerland
*Levosimendan: a unique mechanism of action*

**Alexander Mebazaa**
Paris, France
*Congestion: ino- or dilator?*

**Piergiuseppe Agostoni**
Milan, Italy
*Exercise performance in advanced heart failure*

**John Parissis**
Athens, Greece
*Levosimendan: clinical use and patient quality of life*
ResMed

ResMed Hands-On Tutorials

• Interested in sleep disordered breathing and heart failure?
  Come and attend our Hands-On Tutorials

  **Practical aspects of sleep disordered breathing management in heart failure - The tools in cardiologists hands from screening to treatment**

  Sunday 24/05, 10:00 - 11:00, Hands-On Room 1
  Monday 25/05, 10:00 - 11:00, Hands-On Room 1

  Chair: Dr Christoph Schöbel, Charité Hospital, Berlin, DE

• Want to know more?
  Come and attend our Satellite Symposium

  **SDB in heart failure, time to be serious about it!**
  Sunday 24/05, 12:45 - 13:45, Rome Room

  Chairs: Pr Andrew Coats, London, UK
  Pr Frank Ruschitzka, Zürich, CH

  1. Is it all about central apnoea?
     Dr Peter Van Der Meer, Groningen, NL
  2. What should be the therapeutic goals?
     Pr Martin Cowie, London, UK
  3. Non compliance to PAP therapy - Myth or reality?
     Pr Olaf Oldenburg, Bad Oeynhausen, DE

  And discover our new range of solutions **on booth B70**

SERVE–HF is a landmark study evaluating the use of minute ventilation targeted adaptive servo-ventilation (MV-ASV) for the treatment of sleep-disordered breathing (SDB) in patients with heart failure (HF), throughout Europe and Australia.

SERVE–HF is the first long-term randomised, controlled, international, multicentre study designed to assess the effects of MV-adaptive servo-ventilation on morbidity and mortality in patients with symptomatic chronic heart failure with reduced left ventricular ejection fraction (LVEF) and predominant central sleep apnoea–Cheyne-Stokes respiration (CSA–CSR).

To know more, visit ServeHF.com or visit us on booth B70.
Hands-On Tutorials
Sunday, 24th & Monday 25th May 2015, Hands-On Room 2

You want to

- Understand how you can optimize Mitral Regurgitation treatment with Transcatheter Mitral Valve Repair (TMVR) in Heart Failure patients: from diagnosis to follow-up
- Interact with Transcatheter Mitral Valve Repair device and Transthoracic Echocardiographic Ultrasound system
- Take the opportunity to get answers to your clinical & technical questions thanks to this very interactive session

Valves repaired. Lives improved.
Transcatheter Mitral Valve Repair

Join the following sessions that includes:

45 min Presentation:
Treating Mitral Regurgitation in Heart Failure Patient: From Diagnosis to Follow-up
C. Fernandez-Golfin & J. L. Zamorano, Echocardiographers, Spain

60 min Hands-on Session:
Transcatheter Mitral Valve Repair: Device & Screening
- 30 min: How To Assess Mitral Valve And Mitral Regurgitation With Transthoracic Echocardiographic Ultrasound
  C. Fernandez-Golfin & J. L. Zamorano, Echocardiographers, Spain
- 30 min: Transcatheter Mitral Valve Repair Device
  D. Van Hees, SH Training Manager

Sunday 24/05:
Session 1: 08:30 - 10:30
Session 2: 11:00 - 13:00
Session 3: 14:00 - 16:00

Monday 25/05:
Session 1: 08:30 - 10:30
Session 2: 11:00 - 13:00
Session 3: 14:00 - 16:00

To book your place, please pass by the room or email emea.sh@av.abbott.com or text your name & schedule of your choice +32 478 91 06 28
HANDS-ON-TUTORIAL

Benefits of Ventricular Assist Device therapy for end-stage heart failure patients.

SUNDAY MAY 24, 2015
10:30, 12:30, 14:30
ROOM 3

VISIT OUR BOOTH B40

www.heartware.com
HANDS-ON-TUTORIAL

Benefits of Ventricular Assist Device therapy for end-stage heart failure patients.

SUNDAY MAY 24, 2015
10:30, 12:30, 14:30
ROOM 3

Dr. Juliane Vierecke, German Heart Institute Berlin
- Who should be referred for VAD therapy and when?

Dr. Sebastian Rojas Hernandez, Hannover Medical School
- Hands-On presented by a HeartWare Clinical Specialist.

VISIT OUR BOOTH B40

www.heartware.com
© 2015 HeartWare, Inc. GL1138 Rev01 03/15
City information
For information about our host city, please visit the Registration Area:
• Seville information guides and maps
• Taxi reservations

Cloakroom
A cloakroom is located near the Registration Area; this service is free of charge.

Coffee breaks
Free coffee will be served in the Exhibition and Poster Area on:

- Saturday 23 May 10:00 - 10:30
- Sunday 24 May 10:00 - 11:00 15:45 - 16:30
- Monday 25 May 10:00 - 11:00 15:45 - 16:30
- Tuesday 26 May 10:00 - 11:00

Congress bags
Pick up your bag (including a copy of the Final Programme, the Industry Programme and notepad) next to the Registration Area.

First aid
Participants in need of medical treatment should refer to the ESC staff in the Registration Area.

HFA Members Lounge
Relax, meet with colleagues or enjoy a cup of coffee in this VIP area dedicated to HFA Full members.
The lounge is located on level 1 overlooking the exhibition.

Internet Corner
Open access computers and printers are available in the exhibition please check your floorplan.

Lost and found
Lost and found items can be recovered from the Registration Area.
Lost Badges: a fixed price of €60 will be charged for the replacement of lost badges, at the Registration Assistance Desk.
**Lunch breaks**
Cash points are located throughout the venue; please check your floorplan.

**Opening Hours**
Registration and Speaker Service Centre
- Friday 22 May 14:00 - 18:00
- Saturday 23 May 07:30 - 18:30
- Sunday 24 May 07:30 - 18:30
- Monday 25 May 07:30 - 18:30
- Tuesday 26 May 07:30 - 12:30

**Security**
For security reasons, please ensure your badge is visible at all times during the congress.
Please be aware that when you visit exhibiting company stands during the event or attend industry satellite sessions, presenting your badge for scanning may enable them to retrieve the following personal data: first name(s), last name(s), address, telephone, fax, email, and profile information.

**Speaker Service Centre**
All speakers in scientific sessions are required to upload and validate their presentation at the Speaker Service Centre (SSC) located on level 1, a minimum of 3 hours before the session starts or the day before if the session is at 08:30.
**Continue your education**
All accepted abstracts are published in the online supplement of the European Journal of Heart Failure, on the Scientific Programme & Planner and on the Mobile App.

**e-Library**
All slide presentations, abstracts and electronic posters are available for consultation on-site in the e-Library located in the exhibition.

After the congress, resources will be accessible to HFA full and online members and fellows of the HFA only. Please visit the HFA stand for more information.

**CME Accreditation**
The Heart Failure 2015 congress is accredited by the European Board for Accreditation in Cardiology (EBAC) for 21 hours of External CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works in cooperation with the European Accreditation Council for Continuing Medical Education (EACCME) which is an institution of the European Union of Medical Specialists (UEMS). EBAC credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). Detailed instructions for converting these credits to AMA PRA Category 1 Credits are available on the AMA website.

EBAC Certificates will be available at the Registration desks from Monday 25 May at 12:00.

**Congress News**
Pick up your free daily newspaper of the day! We cover the scientific highlights of the congress for you!
**Mobile App**
Heart Failure 2015 at your fingertips!
- View the entire scientific programme
- Vote during the Mobile App Interactive Sessions
- Search for key opinion leaders, international experts, faculty members
- Create your personal programme and take notes
- Receive latest news on what’s on!

Search for “Heart Failure 2015” in the App Store or in Google Play.
Heart Failure 2015 Mobile App is supported by SERVIER in the form of an unrestricted educational grant.

**Final Programme**
A copy of the congress programme is included in your congress bag.

**Follow us live**
Join the conversation on Twitter! #heartfailure2015 - Check our Facebook page to view the photo album!

**Programme Changes / Date of print**
The date of print is 21 April 2015. The organisers cannot be held liable for any changes in the programme due to external or unforeseen circumstances.
MILLIONS OF PEOPLE IN THE WORLD HAVE HEART FAILURE
ONE WEBSITE CAN HELP THEM UNDERSTAND THEIR CONDITION
AND TAKE THE NECESSARY STEPS TO LIVE FULL AND ACTIVE LIVES

EXPLORE THE SITE TO FIND OUT ABOUT:

WHAT ARE THE WARNING SIGNS?
ADVICE ON WHAT YOU CAN DO
HELPING YOU UNDERSTAND HEART FAILURE
TIPS FOR LIVING WITH HEART FAILURE

WWW.HEARTFAILUREMATTERS.ORG

CAPTIVATING ANIMATIONS
PERSONAL EXPERIENCE VIDEOS
PRACTICAL PATIENT INFORMATION
DOWNLOADABLE TOOLS

Heartfailurematters.org is an educational website for people with heart failure, their families and carers. It was developed by cardiologists, nurses and primary care physicians from the Heart Failure Association of the European Society of Cardiology.

This website is available in numerous languages
HEART FAILURE 2016
CONGRESS ORGANISED BY THE HEART FAILURE ASSOCIATION OF THE ESC

21-24 May
Florence, Italy

Heart Failure: state of the art

#heartfailure2016
www.escardio.org/HFA

HEART FAILURE ASSOCIATION OF THE ESC
EUROPEAN SOCIETY OF CARDILOGY®
EVEN IF YOU CAN’T SEE IT, HEART FAILURE IS

SILENTLY PROGRESSING

HEART FAILURE SHATTERS MILLIONS OF LIVES

LET’S CHANGE THAT TOGETHER

References: